Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Pertuzumab Combined With Lenvatinib for Neoadjuvant Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Single-Arm, Single-Center Clinical Study.

NCT07550972 is registered in ClinicalTrials.gov with Zhejiang Provincial People's Hospital as lead sponsor.

NCT NCT07550972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07550972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Pertuzumab Combined With Lenvatinib for Neoadjuvant Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Single-Arm, Single-Center Clinical Study.
Lead sponsor
Zhejiang Provincial People's Hospital
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
May 1, 2026
Completion date
March 31, 2030
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the head and neck